Liraglutide reduced NLRP3-mediated inflammation, restored mitochondrial dynamics, activated antioxidant defenses via Nrf2, and reversed behavioral changes in a rat model of temporal lobe epilepsy.
Triple mechanism: anti-inflammatory + antioxidant + mitochondrialLiraglutide simultaneously reduced NLRP3 inflammasome activation, activated Nrf2 antioxidant defense, and restored mitochondrial dynamics proteins in the hippocampus of epileptic rats — addressing three key pathological processes at once.
What the researchers found
In 56 Sprague Dawley rats with lithium-pilocarpine-induced status epilepticus: Liraglutide reduced NLRP3 inflammasome pathway activation (↓NLRP3, Caspase-1, IL-1β) in hippocampal tissue. It activated the Nrf2 antioxidant pathway (↑Nrf-2, p-Nrf-2). Mitochondrial dynamics proteins were restored (Pink1, Mfn2, Drp1 normalized). Mitochondrial function in peripheral blood mononuclear cells was altered in both healthy and epileptic rats. Behavioral testing (open field, elevated plus maze, Morris water maze) showed liraglutide reversed the movement-enhancing effect of epilepsy.
Why it matters
About one-third of epilepsy patients don't respond to current anti-seizure medications. Epilepsy is increasingly understood as not just a seizure disorder but a neuroinflammatory and metabolic disease — with mitochondrial dysfunction playing a central role. Liraglutide targets all three problems simultaneously (inflammation, oxidative stress, mitochondrial dysfunction), making it a compelling candidate for a disease-modifying epilepsy treatment rather than just a seizure suppressor.
How the study worked
Fifty-six male Sprague Dawley rats were divided into groups. Temporal lobe epilepsy was induced via low-dose repeated lithium chloride-pilocarpine injections causing status epilepticus. Liraglutide or vehicle was administered. Hippocampal tissue was analyzed by Western blot for inflammatory markers (NLRP3, Caspase-1, IL-1β), antioxidant pathways (Nrf-2, p-Nrf-2), and mitochondrial dynamics proteins (Pink1, Mfn2, Drp1). Peripheral blood mononuclear cell mitochondrial function was assessed by flow cytometry. Behavior was evaluated using open field, elevated plus maze, and Morris water maze tests.
What this study cannot tell us
Rat model of chemically induced epilepsy may not perfectly replicate human TLE, which develops over years. The study assessed markers of inflammation and mitochondrial dynamics but did not directly measure seizure frequency or severity reduction. The behavioral improvements were in non-epileptic behaviors (locomotion, anxiety) rather than seizure outcomes. Short treatment duration may not reflect long-term neuroprotection. Liraglutide doses in rats may not translate directly to human dosing. The specific contribution of GLP-1 receptor activation in brain versus peripheral effects was not separated.
How to read the evidence
This is a well-powered preclinical study (56 rats) with multiple molecular and behavioral outcome measures. The multi-pathway analysis (inflammation, oxidative stress, mitochondrial dynamics) provides mechanistic depth. However, seizure outcomes were not directly measured, and all findings are limited to a rat model.
When this study was published
Published in 2024, this study represents the emerging investigation of GLP-1 agonists for epilepsy — an exciting new direction as the neuroprotective applications of these drugs continue to expand.
The bigger picture
GLP-1 agonists continue to show neuroprotective effects across an expanding range of brain disorders — Alzheimer's, Parkinson's, stroke, TBI, and now epilepsy. The consistent finding across these conditions is that GLP-1 signaling reduces neuroinflammation and supports mitochondrial health. This study adds epilepsy to the list and provides a specific molecular roadmap (NLRP3 → Nrf2 → mitochondrial dynamics) for understanding how these drugs protect the brain.
Questions still open
- Does liraglutide reduce actual seizure frequency and severity in epilepsy models, not just inflammation and behavior?
- Could GLP-1 agonists be used as adjunct therapy for drug-resistant temporal lobe epilepsy in humans?
- Is the neuroprotective effect mediated by direct brain GLP-1 receptor activation or by peripheral metabolic improvements?
Common questions
Could diabetes drugs help treat epilepsy?
How does liraglutide protect the brain in epilepsy?
Read the original research
Exploring Liraglutide in Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy Model in Rats: Impact on Inflammation, Mitochondrial Function, and Behavior.
Biomedicines, 12(10)
Citation
Antmen, Fatma Merve; Fedaioglu, Zeynep; Acar, Dilan; Sayar, Ahmed Kerem; Yavuz, Ilayda Esma; Ada, Ece; Karakose, Bengisu; Rzayeva, Lale; Demircan, Sevcan; Kardouh, Farah; Senay, Simge; Kolgazi, Meltem; Suyen, Guldal; Oz-Arslan, Devrim. (2024). Exploring Liraglutide in Lithium-Pilocarpine-Induced Temporal Lobe Epilepsy Model in Rats: Impact on Inflammation, Mitochondrial Function, and Behavior.. Biomedicines, 12(10). https://doi.org/10.3390/biomedicines12102205